These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18534730)

  • 1. Spurious hyperphosphatemia in patients on hemodialysis with catheters.
    Schiller B; Virk B; Blair M; Wong A; Moran J
    Am J Kidney Dis; 2008 Sep; 52(3):617-20. PubMed ID: 18534730
    [No Abstract]   [Full Text] [Related]  

  • 2. Alteplase as hemodialysis catheter locking solution and spurious hyperphosphatemia.
    Sombolos K; Bamichas G; Hatsiou V; Fragidis S; Rizos A; Natse T; Fytili C
    J Vasc Access; 2011; 12(3):269. PubMed ID: 21218384
    [No Abstract]   [Full Text] [Related]  

  • 3. Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter.
    Cachat F; Bardy D; Durussel C; Di Paolo E
    Pediatr Nephrol; 2006 Feb; 21(2):301-2. PubMed ID: 16328539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spurious Hyperphosphatemia in a Patient with Chronic Kidney Disease - a Rare Case of Alteplase Contamination.
    Khan ZUN; Ahmed S; Siddiqui A; Siddiqui I
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting tissue plasminogen activator use and success in in-center hemodialysis patients.
    Kosa SD; Ye C; Thabane L; Gafni A; Lok CE
    J Vasc Access; 2018 Mar; 19(2):146-152. PubMed ID: 28983900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of intensive versus standard hemodialysis central venous catheter dysfunction protocol using rt-PA: a quality assurance initiative.
    Wilson JA; Mossop P; Soroka SD; Dipchand C; Drost S; Sheehy N; Tennankore K
    J Vasc Access; 2016; 17(2):143-50. PubMed ID: 26847735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.
    Hemmelgarn BR; Moist LM; Lok CE; Tonelli M; Manns BJ; Holden RM; LeBlanc M; Faris P; Barre P; Zhang J; Scott-Douglas N;
    N Engl J Med; 2011 Jan; 364(4):303-12. PubMed ID: 21268722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of reteplase for thrombolysis of hemodialysis catheters at a community and academic regional medical center.
    Hyman G; England M; Kibede S; Lee P; Willets G
    Nephron Clin Pract; 2004; 96(2):c39-42. PubMed ID: 14988596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue plasminogen activator use in maintaining patency in hemodialysis access catheters.
    Walton T; Eyrich H
    Am J Kidney Dis; 2001 Feb; 37(2):453-4. PubMed ID: 11157395
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review.
    Hilleman D; Campbell J
    Pharmacotherapy; 2011 Oct; 31(10):1031-40. PubMed ID: 21950645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of tissue plasminogen activator infusion to re-establish function of tunneled hemodialysis catheters.
    Dowling K; Sansivero G; Stainken B; Siskin G; Dolen E; Ahn J; Mitchell N
    Nephrol Nurs J; 2004; 31(2):199-200. PubMed ID: 15114800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteplase for blood flow restoration in hemodialysis catheters: a multicenter, randomized, prospective study comparing "dwell" versus "push" administration.
    Vercaigne LM; Zacharias J; Bernstein KN
    Clin Nephrol; 2012 Oct; 78(4):287-96. PubMed ID: 22541682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteplase versus urokinase for occluded hemodialysis catheters.
    Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
    Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of reteplase in poorly functioning hemodialysis catheters.
    Falk A; Samson W; Uribarri J; Vassalotti JA
    Clin Nephrol; 2004 Jan; 61(1):47-53. PubMed ID: 14964457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-operative intracranial hemorrhage related to using t-PA for declotting an occluded hemodialysis catheter: A cautionary tale.
    Plonsker J; Tan LA; Munoz LF
    J Clin Neurosci; 2016 Oct; 32():145-7. PubMed ID: 27301545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The case of the floating gel.
    Srivastava R; Murphy MJ; Card J; Severn A; Fraser CG
    J Clin Pathol; 2004 Dec; 57(12):1333-4. PubMed ID: 15563680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tackling the Achilles' heel of hemodialysis.
    Winkelmayer WC
    N Engl J Med; 2011 Jan; 364(4):372-4. PubMed ID: 21268730
    [No Abstract]   [Full Text] [Related]  

  • 18. Short and long alteplase dwells in dysfunctional hemodialysis catheters.
    Macrae JM; Loh G; Djurdjev O; Shalansky S; Werb R; Levin A; Kiaii M
    Hemodial Int; 2005 Apr; 9(2):189-95. PubMed ID: 16191068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteplase use for clotted catheters.
    Macon EJ
    Semin Dial; 2002; 15(1):72. PubMed ID: 11874599
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review.
    Clase CM; Crowther MA; Ingram AJ; Cinà CS
    J Thromb Thrombolysis; 2001 Apr; 11(2):127-36. PubMed ID: 11406727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.